Introduction
HLA class II molecules are normally expressed on the surface of antigen presenting cells, such as dendritic cells and macrophages, and play an essential role in the induction of immune responses (1, 2) . The detection of HLA class II expressing thyroid follicular cells (TFC)' in thyroid autoimmune diseases such as Graves' disease (GD) and Hashimoto's thyroiditis (3) led to the suggestion that this "aberrant" class II expression might result in the activation of thyroid autoreactive lymphocytes and thus be the initiating and/or perpetuating factor of thyroid autoimmune disease (4) . The findings that Graves' disease TFC are capable of presenting antigen (5) and are recognized by autologous T lymphocytes, derived from the thyroid gland (6, 7) seemed to support this hypothesis.
However, subsequently it was found that HLA class II expressing TFC were also present in thyroid diseases not considered as autoimmune, such as toxic and nontoxic nodular goiter and thyroid carcinoma (8-1 1). The occurrence of focal lymphocytic infiltrates and of low titer thyroid autoantibodies are also common in these conditions (8, 9, 12, 13) . Two alternative explanations of this finding are possible: (a) The above mentioned disorders are autoimmune, which implies that the spectrum of thyroid autoimmune diseases is much wider than hitherto assumed; or (b) that HLA class II expression on TFC may occur without progressing to the induction of autoimmune disease, for which additional factors must be involved.
The validity of these possibilities was checked by comparing the immunostimulatory function of HLA class II expressing TFC in classical autoimmune disease such as GD and in presumably nonautoimmune thyroid disease such as nontoxic goiter (NTG).
Methods

Patients
Six patients with nontoxic goiter (five women, one man, aged 56±15, range 29-80 yr) and six patients with Graves' disease (5 women, 1 man, aged 35±10, range 22-53 yr) were studied. Patients with NTG had longstanding multinodular goiters of gradually increasing size. Radionuclide thyroid scans with 9TC showed an irregular patchy uptake. Serum total thyroxine and triiodothyronine concentrations were within the normal range. Thyroid autoantibodies (against thyroglobulin and thyroid microsomal antigen) were measured with the tanned red cell hemagglutination techniques (Burroughs Wellcome, Beckenham, UK). Antibodies against microsomal antigen were present in two patients (titer 1:400). One of these two had additional antibodies against thyroglobulin (titer 1:320). None of the patients received any thyroid hormone or antithyroid drug treatment. Patients underwent thyroidectomy and were histologically classified as nodular goiter. Lymphocytic infiltration of the thyroid was also assessed on the basis of hematoxylin-eosin staining.
Patients with GD had small diffuse goiters and two had mild endocrine ophthalmopathy. Thyroid scans showed a diffusely high uptake of radionuclide characteristic of GD. All patients had clinical and laboratory evidence of severe hyperthyroidism at the time ofdiagnosis. Thyroid autoantibodies against thyroglobulin were present in two patients (titers 1:40 and 1:320) and against thyroid microsomal antigen in five patients (titers range: 1:1,600-1:6,400). All patients underwent thyroidectomy within 18 mo after diagnosis for recurrent hyperthyroidism in spite of continuous antithyroid drug treatment. At the time of surgery patients were euthyroid under low doses ofeither methimazole or prothiucil. In all cases the histological diagnosis was toxic diffuse goiter.
Preparation ofthyroid tissue 5 X 5 mm tissue blocks were snap frozen in liquid nitrogen and 5-gm frozen cryostat sections were cut from each sample. Sections were fixed in acetone for 5 min. The degree of in vivo HLA class II expression on TFC in the individual patients was then studied by immunofluorescence staining as described below using a monoclonal anti-HLA-DR antibody (Becton Dickinson & Co., Oxnard, CA) directed against the nonpolymorphic region of the DR molecule.
The remaining thyroid tissue was dispersed with collagenase (type IV; Cooper Biomedical, Malvern, PA, 5 mg/ml, in RPMI 1640 medium containing 15% fetal calf serum; Gibco Laboratories, Paisley, Scotland) for 3 h, and pipetted through a 200-gm mesh. The red blood cells were lysed with an ammonium chloride buffer. The resulting cells were either cryopreserved in liquid nitrogen or used directly. Further separations were performed as follows.
TFC. Cells were incubated in RPMI (supplemented with 15% FCS, 100 U/ml penicillin, and 100 gg/ml streptomycin) in 25 cm2 flasks (Becton Dickinson) at 370C in 95% air/5% CO2 and 95% humidity for 24 h. Nonadherent cells were then removed and processed as described below. Macrophages were mostly nonadherent after 24 h incubation and the few adherent ones could be removed by vigorous pipetting. The remaining adherent cells were removed from the plastic support by a 10-min exposure to trypsin (Gibco trypsin solution, 0.25%) and washed twice. The cell population thus obtained was identified as TFC (purity > 95%) by staining with a serum ofa patient with GD containing a high titer of antimicrosomal antibodies as previously described (6) . Macrophage contamination was estimated as 1.2±1.74% by immunofluorescence staining as described below using the monoclonal antibody anti-Leu M3 (Becton Dickinson), which is specific for mature macrophages and monocytes. In two ofthe patients ofeach group TFC were additionally stained with anti HLA-DR monoclonal antibody (Becton Dickinson). This was done before and after exposure to recombinant human interferon-y (IFN--y; Boehringer Ingelheim, Vienna, Austria; 50 U/ml for 3 d in RPMI 1640 containing 2.5% human serum).
Macrophage-enriched population. The Stimulation of autologous PBMC. Graves' disease TFC stimulated autologous PBMC more efficiently than nontoxic goiter TFC (comparison of stimulation indices: P < 0.05; Table IV ). Counts per minute ranged from 307 to 3,049 (median 1,323) in NTG and from 1,124 to 11.748 (median 4,647) in GD. Significant responses were observed in all but one patient with GD (patient B). This patient had no thyroid autoantibodies, a very moderate lymphocytic infiltration of the thyroid gland and only few HLA class II' TFC at the time of surgery and may have been in remission. Special attention was thus paid to the question, whether in NTG TFC from patients in whom the presence of thyroid autoantibodies might suggest 
Discussion
Previous work on Graves' disease has emphasized the capacity of HLA class II expressing TFC to present antigen to autoreactive T cells, which infiltrate the affected tissue (6, 7). However HLA class II expression on TFC has subsequently been found in diseases presumed to be nonautoimmune, such as nodular goiter (8) (9) (10) . It was thus of interest to compare the immunostimulatory function of HLA class II' TFC in nontoxic nodular goiter and Graves' disease.
In accordance with earlier studies (8) HLA class II expressing TFC were present in patients with GD as well as with NTG, although the number of positive cells tended to be higher in GD than in NTG (Table I) . HLA class II expression was always associated with lymphocytic infiltration, although in some of the samples very few lymphocytes were detectable. This may however be due to the fact that no serial sections TFC were similar to those induced by thyroid macrophages, but weaker than the ones initiated by PBMC. (17, 18) . Thyroid infiltrating T cells were screened for their capacity to respond to autologous TFC. Due to the limited number of cells available these cannot be tested directly, and so were cultured with OKT3 and IL-2 to initiate growth nonspecifically, by using a variation of a published method (14) . It is noteworthy that only the T cells from GD responded to autologous TFC (Figs. 1 and 2) . As It is interesting that two NTG patients had low titer thyroid autoantibodies in spite of a total lack of T lymphocytic autoantigen recognition. This may indicate that local inflammatory reactions in the thyroid gland, although nonspecific per se may, via a leakage of thyroid antigens, still result in B cell activation and subsequent autoantibody production.
The validity of our assumptions is obviously dependent on the fact that the stimulatory effects observed are induced by the TFC themselves and not by contaminating cells such as dendritic cells and macrophages. However dendritic cells, which have been considered to be of importance as intrathyroidal antigen presenters in thyroid disease (22) , are not adherent after 24 h incubation (23, 24) and thus of no influence in our system. Macrophage contamination was estimated by immunostaining with aLeuM3 and by microscopic examination and was < 2%. As TFC expressing class II induce similar proliferation of allogeneic PBMC as HLA class II+ thyroid macrophages (64% LeuM3+) it seems evident that the stimulatory effect of the TFC population is induced by the TFC themselves.
Our results thus demonstrate that in spite of the similar alloantigen presenting capacity of NTG and GD TFC, thyroid autoantigen presentation by HLA class II+ TFC occurs only in GD, but not in NTG. The two diseases thus do not share a common autoimmune background. HLA class II expression on TFC is a necessary requirement, but by itself not sufficient for the induction of autoimmune disease.
What are the other necessary components to the development of thyroid autoimmunity? Currently this is not understood in detail. Evidence suggesting that autoimmune thyroid disease is due to a genetically determined organ specific defect in suppressor T lymphocytes has recently been reviewed by Volpe (25) . The fact that thyroid autoimmune disease is HLA-DR associated (26) 
